Abstract:Background: In recent years, immunotherapy has changed the therapeutic landscape of hepatocellular carcinoma (HCC). Since the efficacy of immunotherapy is closely related to the tumor microenvironment (TME), in this study, we constructed a prognostic model based on TME to predict the prognosis and immunotherapy effect of HCC patients. Methods: Transcriptome and follow-up data of 374 HCC patients were acquired from the TCGA Cancer Genome Atlas (TCGA) database. The immune/stromal/estimate scores (TME scores) and tumor purity were calculated using the ESTIMATE algorithm and the module most associated with TME scores were screened by the weighted gene co-expression network analysis (WGCNA). A TME score-related prognostic model was constructed and patients were divided into a high-risk group and a low-risk group. Kaplan-Meier survival curves and receiver operator characteristic curve (ROC) were used to evaluate the performance of the TME risk prognostic model and validated with the external database International Cancer Genome Consortium (ICGC) cohort. Combined with clinicopathologic factors, a prognostic nomogram was established. The nomogram's ability to predict prognosis was assessed by ROC, calibration curve, and the decision curve analysis (DCA). Gene Set Enrichment Analyses (GSEA) were conducted to explore the underlying biological functions and pathways of this risk signature. Moreover, the possible correlation of risk signature with TME immune cell infiltration, immune checkpoint inhibitor (ICI) treatment response, single-nucleotide polymorphisms (SNPs), and drug sensitivity were assessed. Finally, real-time PCR was used to verify the gene expression levels in normal liver cells and cancer cells. Results: KM survival analysis results indicated that high immune/stromal/estimate score groups were closely associated with a better prognosis, while the tumor purity showed a reverse trend ( p < 0.01). WGCNA demonstrated that the yellow module was significantly correlated with the TME score. The 5-genes TME risk signature was built to predict the prognosis of patients with HCC including DAB2 , IL18RAP , RAMP 3, FCER1G , and LHFPL2 . Patients with a low-risk score have higher levels of tumor-infiltrating immune cells and higher expression of immune checkpoints, which may be more sensitive to immunotherapy. Conclusion: It provided a theoretical basis for predicting the prognosis and personalized treatment of patients with HCC.

TMEM147 Correlates with Immune Infiltration and Serve As a Potential Prognostic Biomarker in Hepatocellular Carcinoma

Comprehensive Analysis of Immune-Related Prognosis of TK1 in Hepatocellular Carcinoma

Characterization of the Clinical Significance and Immunological Landscapes of a Novel TMEMs Signature in Hepatocellular Carcinoma and the Contribution of TMEM201 to Hepatocarcinogenesis.

Comprehensive Study of Tumor Immune Microenvironment and Relevant Genes in Hepatocellular Carcinoma Identifies Potential Prognostic Significance

TMEM106C Contributes to the Malignant Characteristics and Poor Prognosis of Hepatocellular Carcinoma.

TMEM206 is a Potential Prognostic Marker of Hepatocellular Carcinoma

TMEM88 is a Prognostic Biomarker and Correlates with Immune Infiltrates in Hepatocellular Carcinoma

Overexpression of TMEM79 Combined with SMG5 is Related to Prognosis, Tumor Immune Infiltration and Drug Sensitivity in Hepatocellular Carcinoma

TMEM147 Promotes Hepatocellular Carcinoma Progress by Inducing EGFR/MAPK Activity

Immune Classifier-Based Signatures Provide Good Prognostic Stratification and Predict the Clinical Benefits of Immune-Based Therapies for Hepatocellular Carcinoma

In-depth Characterization of the Biomarkers Based on Tumor-Infiltrated Immune Cells Reveals Implications for Diagnosis and Prognosis in Hepatocellular Carcinoma.

Identification of a Novel Signature Based on Macrophage-Related Marker Genes to Predict Prognosis and Immunotherapeutic Effects in Hepatocellular Carcinoma.

Comprehensive Analysis Reveals TSEN54 As a Robust Prognosis Biomarker and Promising Immune-Related Therapeutic Target for Hepatocellular Carcinoma.

Comprehensive Pan-Cancer Analysis Reveals Prognostic Implications of TMEM92 in the Tumor Immune Microenvironment

Transmembrane protein 147, as a potential Sorafenib target, could expedite cell cycle process and confer adverse prognosis in hepatocellular carcinoma

TMEM200A is a Potential Prognostic Biomarker and Correlated with Immune Infiltrates in Gastric Cancer.

The Expression of TMEM74 in Liver Cancer and Lung Cancer Correlating with Survival Outcomes

A Novel Approach for the Analysis of Single-Cell RNA Sequencing Identifies TMEM14B As a Novel Poor Prognostic Marker in Hepatocellular Carcinoma.

TMEM41A overexpression correlates with poor prognosis and immune alterations in patients with endometrial carcinoma

Comprehensive Analysis to Identify the Epithelial–Mesenchymal Transition-Related Immune Signatures As a Prognostic and Therapeutic Biomarkers in Hepatocellular Carcinoma

Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma